key: cord-0846011-qs97uob0
authors: Silvas, Jesus A.; Vasquez, Desarey Morales; Park, Jun-Gyu; Chiem, Kevin; Allué-Guardia, Anna; Garcia-Vilanova, Andreu; Platt, Roy Neal; Miorin, Lisa; Kehrer, Thomas; Cupic, Anastasija; Gonzalez-Reiche, Ana S.; van Bakel, Harm; García-Sastre, Adolfo; Anderson, Tim; Torrelles, Jordi B.; Ye, Chengjin; Martinez-Sobrido, Luis
title: Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice
date: 2021-08-10
journal: J Virol
DOI: 10.1128/jvi.00402-21
sha: 113a1954dffe7fd79f14435535f72033a3d6a329
doc_id: 846011
cord_uid: qs97uob0

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the viral pathogen responsible for the current coronavirus disease 2019 (COVID-19) pandemic. As of 19 May 2021, John Hopkins University’s COVID-19 tracking platform reported 3.3 million deaths associated with SARS-CoV-2 infection. Currently, the World Health Organization has granted emergency use listing (EUL) to six COVID-19 vaccine candidates. However, much of the pathogenesis observed during SARS-CoV-2 infection remains elusive. To gain insight into the contribution of individual accessory open reading frame (ORF) proteins in SARS-CoV-2 pathogenesis, we used our recently described reverse-genetics system approach to successfully engineer recombinant SARS-CoV-2 (rSARS-CoV-2) constructs; we removed individual viral ORF3a, −6, −7a, −7b, and −8 proteins from them, and we characterized the resulting recombinant viruses in vitro and in vivo. Our results indicate differences in plaque morphology, with ORF-deficient (ΔORF) viruses producing smaller plaques than those of the wild type (rSARS-CoV-2/WT). However, growth kinetics of ΔORF viruses were like those of rSARS-CoV-2/WT. Interestingly, infection of K18 human angiotensin-converting enzyme 2 (hACE2) transgenic mice with the ΔORF rSARS-CoV-2s identified ORF3a and ORF6 as the major contributors of viral pathogenesis, while ΔORF7a, ΔORF7b, and ΔORF8 rSARS-CoV-2s induced pathology comparable to that of rSARS-CoV-2/WT. This study demonstrates the robustness of our reverse-genetics system to generate rSARS-CoV-2 constructs and the major role for ORF3a and ORF6 in viral pathogenesis, providing important information for the generation of attenuated forms of SARS-CoV-2 for their implementation as live attenuated vaccines for the treatment of SARS-CoV-2 infection and associated COVID-19. IMPORTANCE Despite great efforts put forward worldwide to combat the current coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a human health and socioeconomic threat. Insights into the pathogenesis of SARS-CoV-2 and the contribution of viral proteins to disease outcome remain elusive. Our study aims (i) to determine the contribution of SARS-CoV-2 accessory open reading frame (ORF) proteins to viral pathogenesis and disease outcome and (ii) to develop a synergistic platform combining our robust reverse-genetics system to generate recombinant SARS-CoV-2 constructs with a validated rodent model of infection and disease. We demonstrate that SARS-CoV-2 ORF3a and ORF6 contribute to lung pathology and ultimately disease outcome in K18 hACE2 transgenic mice, while ORF7a, ORF7b, and ORF8 have little impact on disease outcome. Moreover, our combinatory platform serves as a foundation for generating attenuated forms of the virus to develop live attenuated vaccines for the treatment of SARS-CoV-2.

generating attenuated forms of the virus to develop live attenuated vaccines for the treatment of SARS-CoV-2.

KEYWORDS SARS-CoV-2, COVID-19, K18 hACE2 transgenic mice, ORF3a, ORF6, ORF7a, ORF7b, ORF8, hACE2, pathogenesis C oronaviruses (CoVs) are enveloped, positive-sense, single-stranded RNA viruses that cause both mild and lethal upper respiratory illness in humans (1-3). Highly pathogenic and lethal severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS) CoVs were first identified in early 2000 and 2010 as spillover events to humans from horseshoe bats and dromedary camels, respectively (2, 4, 5) . In December 2019, a respiratory infectious disease disseminated throughout the Chinese city of Wuhan, and by the spring of 2020, it had spread worldwide (6) . A novel coronavirus, SARS-CoV-2, was identified as the etiological agent of the new coronavirus disease 2019 (COVID-19) pandemic (6) (7) (8) .

The SARS-CoV-2 genome encodes 16 nonstructural proteins (NSPs) and 6 accessory proteins, each encoded by independent open reading frames (ORFs) (9) . It has been described that both coronavirus NSP and ORF proteins play important roles in viral replication and transcription, evasion of host immune responses, and viral dissemination (10, 11) . In particular, SARS-CoV ORF3a has been implicated as an inducer of membrane rearrangement and cell death (12) (13) (14) . SARS-CoV ORF3b, ORF6, and nucleocapsid (N) proteins have been described to counteract the host immune interferon (IFN) responses (15) . Moreover, SARS-CoV ORF7a protein has also been shown to inhibit cellular protein synthesis and activation of p38 mitogen-activated protein kinase (16) . Conversely, coronavirus ORF7b has been reported to have a Golgi localization signal, where it becomes incorporated into the virion; however, no additional studies have delved into any further functions (17, 18) . Furthermore, with regard to SARS-CoV-2, early clinical isolates identified a 382-nucleotide deletion leading to a truncated ORF7b protein and removal of the ORF8 transcription signal (19) . Lastly, SARS-CoV-2 ORF8 has been postulated to play a minor role in disease outcome, as natural SARS-CoV-2 strains containing deletions in ORF8 have been isolated from individuals presenting with COVID-19 (20) . Nevertheless, only a limited number of studies have examined the contribution of coronavirus NSP or ORF proteins to pathogenesis and disease outcome in animal models of infection.

To examine the contribution of accessory proteins in the pathogenicity of SARS-CoV-2, we used our previously described reverse-genetics approach based on the use of a bacterial artificial chromosome (BAC) to rescue recombinant SARS-CoV-2 (rSARS-CoV-2) with deletions of individual accessory ORF proteins (21) . We were able to successfully rescue rSARS-CoV-2 constructs deficient in ORF3a, ORF6, ORF7a, ORF7b, and ORF8 individually. The in vitro characterization of each deficient-ORF (DORF) virus revealed a distinct difference in plaque phenotype from that of the recombinant wildtype SARS-CoV-2 (rSARS-CoV-2/WT). This phenotypic change, however, did not affect the viral growth kinetics, since all DORF rSARS-CoV-2s replicated similarly to the rSARS-CoV-2/WT. Interestingly, we observed changes in pathogenesis between the WT and DORF rSARS-CoV-2s in the established K18 human angiotensin-converting enzyme 2 (hACE2) transgenic mouse model of SARS-CoV-2 infection (22) . In contrast to the WT and the ORFD7a, ORFD7b, and ORFD8 rSARS-CoV-2s, the ORFD3a and ORFD6 rSARS-CoV-2s induced less pathology and resulted in 75% and 50% survival rates, respectively. Furthermore, both the ORFD3a and ORFD6 rSARS-CoV-2s had lower viral titers (10 2 PFU/ml) at 2 days postinfection (p.i.) and by 4 days p.i. were no longer detected in nasal turbinates. In contrast, ORFD6 viral strain replication in the lungs reached 10 5 PFU/ml at 2 days p.i. and only decreased by ;2 log 10 at 4 days p.i. ORFD3a virus replication reached only 10 2 PFU/ml at 2 days p.i. and was not detected by 4 days p.i. in the lungs. Both the ORFD7a and ORFD7b rSARS-CoV-2s induced pathologies similar to that produced by rSARS-CoV-2/WT and resulted in a 25% survival rate. By merging our in vitro and in vivo data, we have been able to generate insights into the contribution of SARS-CoV-2 accessory ORF proteins in the pathogenesis and disease outcome of SARS-CoV-2 infection. These essential data also pave the way for further designing and developing of live attenuated vaccines against SARS-CoV-2.

Generation of BACs with deletions of individual accessory ORF proteins. The SARS-CoV-2 genome, which was divided into 5 fragments and chemically synthesized, was assembled into a single bacterial artificial chromosome (BAC) that led to efficient virus rescue after transfection into Vero E6 cells using Lipofectamine 2000 (21) . Fragment 1 included the SARS-CoV-2 ORF accessory proteins. Using standard gene-engineering approaches, we systematically deleted, individually, ORF3a, ORF6, ORF7a, ORF7b, or ORF8 from fragment 1 using PCR and primer pairs containing BsaI type IIS restriction endonuclease sites. After being confirmed by Sanger sequencing (data not shown), fragment 1 containing the individual deletions of the ORF3a, ORF6, ORF7a, ORF7b, or ORF8 accessory protein were reassembled into the BAC (Fig. 1) .

Rescue of DORF rSARS-CoV-2s. BACs with individual deletions of an accessory ORF were transfected into Vero E6 cells for the recovery of DORF rSARS-CoV-2s, according to our previously described protocol (21) . At 72 h posttransfection, tissue culture supernatants (passage 0 [P0]) were collected to inoculate fresh Vero E6 cells (P1). Supernatants were then collected from P1 at 72 h p.i., and viral titers, defined as numbers of PFU per milliliter, were determined as previously described (21) . To verify the rescue of each DORF rSARS-CoV-2, indirect immunofluorescence was performed using antibodies directed at the nucleocapsid (N) and spike (S) proteins ( Fig. 2A) . We next verified the individual deletion of each ORF from rSARS-CoV-2 using reverse transcription-PCR (RT-PCR) procedures to amplify the viral N gene (control) and the regions which cover the corresponding individual ORF deletions (Fig. 2B ). All the DORF rSARS-CoV-2s and rSARS-CoV-2/WT produced an RT-PCR product of approximately 1.2 kb corresponding to the N gene, whereas amplified regions that cover the corresponding ORF deletions were smaller in the DORF rSARS-CoV-2 constructs than in rSARS-CoV-2/ WT (Fig. 2B) , demonstrating the deletion of the individual ORFs from the viral genomes. Individual deletions of the viral proteins from the DORF rSARS-CoV-2s were further confirmed by Sanger sequencing of PCR products (Fig. 2C ) and deep sequencing analysis of the entire viral genome (Fig. 3) . These data demonstrate that each DORF rSARS-CoV-2 construct contained a deletion of its individual ORF accessory protein. Characterization of the DORF rSARS-CoV-2 constructs in vitro. We next proceeded to characterize each DORF rSARS-CoV-2 construct in vitro (Fig. 4) . Previous studies have shown that manipulation of the viral genome can affect the phenotypes of viral plaques; therefore, as an initial step, we proceeded to investigate whether deletion of individual accessory ORFs had an impact on the rSARS-CoV-2 plaque phenotype (23) , as some studies have linked changes in plaque phenotype to attenuation or disease outcome (24, 25) . Interestingly, we noticed an effect on the plaque phenotypes of all DORF rSARS-CoV-2 constructs compared to that on rSARS-CoV-2/WT at all times p.i. studied (24, 48, 72 , and 96 h) (Fig. 4A) . We further confirmed these results by measuring the diameters of the plaques of the WT and ORF-deficient rSARS-CoV-2s on Vero E6 cell monolayers (Fig. 4B) . Except for ORFD7b rSARS-CoV-2, all the other ORF-deficient rSARS-CoV-2s had smaller plaque phenotypes than WT rSARS-CoV-2 at any of the studied time points (Fig. 4A and B ). Next, we compared the growth kinetics of the DORF rSARS-CoV-2s to that of rSARS-CoV-2/WT in Vero E6 cells. To this end, viral titers in the tissue culture supernatants from Vero E6 cells infected (multiplicity of infection [MOI], 0.01) with the WT or DORF rSARS-CoV-2 collected at 12, 24, 48, 72, and 96 h p.i. were determined by plaque assay (Fig. 4C ). No statistically significant differences between the WT and ORFD3a, ORFD6, and ORFD7b rSARS-CoV-2s were observed at any times p.i., except for the replication of ORFD7a and ORFD8 rSARS-CoV-2s, which was significantly different (;1 log 10 ) than that of rSARS-CoV-2/WT at 12 and 24 h p.i. (Fig. 4C) . Peak viral titers for all DORF rSARS-CoV-2s and rSARS-CoV-2/WT were observed between 24 and 48 h p.i., with viral titers decreasing (;1 log 10 ) at later times with the WT or the ORFD3a, ORFD6, ORFD7a, ORFD7b, or ORFD8 rSARS-CoV-2. At 24 h p.i., cells were fixed and immunostained with a cross-reactive polyclonal antibody against SARS-CoV N protein and a cross-reactive monoclonal antibody against SARS-CoV S protein (3B4). Rhodamine red goat anti-rabbit and FITC rabbit anti-mouse secondary antibodies were used, and nuclei were visualized with DAPI. Scale bars, 100 mm. (B) RT-PCR. Vero E6 cells (6-well plate format, 10 6 cells/well) were mock infected or infected (MOI of 0.1) with the WT or a DORF rSARS-CoV-2, and total RNA was extracted at 24 h p.i. Regions in the viral genome corresponding with the deletion were amplified, and the N gene was amplified as an internal control. All the products were separated on a 0.8% agarose gel. MW, molecular weight. (C) Sequencing. RT-PCR products from panel B were gel purified and subjected to Sanger sequencing. The consensus sequences in the genomes of both the WT and a DORF rSARS-CoV-2 downstream of the deleted gene are indicated in blue, the intergenic regions between viral genes are shown in yellow, the genes deleted from the DORF rSARS-CoV-2s are indicated in green, and the viral genes upstream of the deleted ORFs in the rSARS-CoV-2s are shown in red.

p.i., consistent with previous studies with SARS-CoV-2 natural isolates (26, 27) . To further assess the effect of ORF deletions on viral fitness and replication, we determined growth kinetics in human HEK293T and A549 cells stably expressing the hACE2 receptor (hACE2-HEK293T and hACE2-A549 cells, respectively), which have been shown to be permissive to SARS-CoV-2 infection (28, 29) . We observed that in hACE2-HEK293T ( Fig. 4D ) and hACE2-A549 ( Fig. 4E ) cells, the WT and ORF-deficient rSARS-CoV-2 infections peaked at 48 h p.i. and began to decrease at the latter time points, a trend similar to what we observed in Vero E6 cells (Fig. 4C) . However, in contrast to the WT and other ORF-deficient rSARS-CoV-2s, both the ORFD7a and ORFD8 rSARS-CoV-2s replicated significantly less after 12 h p.i. Moreover, we observed a decrease in ORFD6 rSARS-CoV-2 titers after the peak at 48 h p.i. All together, these results suggest that despite slight differences in plaque phenotype, DORF rSARS-CoV-2s have replication kinetics similar to that of rSARS-CoV-2/WT in Vero E6 cells, while the ORFD7a, ORFD8, and ORFD6 rSARS-CoV-2s have altered replication capabilities in human cell lines, especially in hACE2-A549 cells, which are competent in innate immune responses.

Characterization of DORF rSARS-CoV-2s in vivo. Coronavirus ORF accessory proteins have been implicated as virulence factors and contribute to both pathogenicity and disease outcome (12, 13, 20, (30) (31) (32) . Therefore, we proceeded to further investigate the contribution of SARS-CoV-2 ORF3a, ORF6, ORF7a, ORF7b, and ORF8 to viral pathogenicity and disease outcome in our previously established K18 hACE2 transgenic mouse model of SARS-CoV-2 infection and COVID-19 disease (22) . Four-to 6week-old female mice (n = 4) were mock (phosphate-buffered saline [PBS]) infected or infected (10 5 PFU) with rSARS-CoV-2/WT or with one of the DORF rSARS-CoV-2s and observed for 14 days for morbidity (body weight loss) and mortality (survival) (Fig. 5) .

Our results indicate similar decreases in body weight percentages up to 5 days p.i., from which ORFD3a and ORFD7b rSARS-CoV-2-infected mice began to recover (Fig.  5A) . Interestingly, mice infected with ORFD6 and ORFD7a rSARS-CoV-2s continued to lose body weight until 7 and 8 days p.i., respectively, and to start to recover (Fig. 5A ). All mice infected with the WT or ORFD8 rSARS-CoV-2 succumbed to viral infection by 6 or 7 days p.i., respectively (Fig. 5B ). Our continued observations of mice infected with ORFD3a, ORFD6a, ORFD7a, and ORFD7b rSARS-CoV-2s identified survival rates of 75%, 50%, 25%, and 25%, respectively (Fig. 5B) . Upon full comparison, it is worth noting that despite the early onset of morbidity observed in mice infected with the ORFD3a rSARS-CoV-2, 3 out of 4 mice survived viral infection, suggesting that ORF3a may play an important role in viral pathogenesis. This early onset of morbidity and quick recovery may be the result of an active immune response to viral infection and, therefore, viral clearance.

We next evaluated viral replication in nasal turbinates and lungs of K18 hACE2 transgenic mice infected with the WT or DORF rSARS-CoV-2 at 2 and 4 days p.i. (Fig. 6) . At 2 days p.i., the WT and ORFD6 rSARS-CoV-2 were detected in nasal turbinates in all mice, with rSARS-CoV-2/WT reaching titers of up to 5 Â 10 3 PFU/ml, while ORFD6 rSARS-CoV-2 peaked at 5 Â 10 2 PFU/ml. We detected ORFD3a rSARS-CoV-2 (10 2 PFU/ ml) in only 50% of infected mice, while ORFD7b rSARS-CoV-2 replicated up to 3 Â 10 3 PFU/ml in 75% of infected mice. Only 50% of mice had detectable levels (ranging between 0.5 Â 10 3 and 1 Â 10 3 PFU/ml) of ORFD8 rSARS-CoV-2 (Fig. 6A) . Interestingly, out of all the DORF rSARS-CoV-2s tested, ORFD7a replicated in the nasal turbinate to levels (5 Â 10 4 PFU/ml) higher than those observed with rSARS-CoV-2/WT. By 4 days p. i., ORFD3a and ORFD6 rSARS-CoV-2s were no longer detected in nasal turbinates, while 75% of mice infected with rSARS-CoV-2/WT had viral titers ranging between 5 Â 10 1 and 5 Â 10 2 PFU/ml. ORFD7a, ORFD7b, and ORFD8 rSARS-CoV-2s replicated to lower levels (;5 Â 10 1 PFU/ml) than rSARS-CoV-2/WT (Fig. 6A) . In the lungs, the WT and ORFD6 and ORFD7a rSARS-CoV-2s were detected at levels of ;10 5 PFU/ml at 2 days p.i. (Fig. 6B ). Viral titers of ORFD7b and ORFD8 rSARS-CoV-2s (;10 4 PFU/ml) and ORFD3a (;0.5 Â 10 2 PFU/ml) rSARS-CoV-2 were lower than those of rSARS-CoV-2/WT (Fig. 6B) . Interestingly, by 4 days p.i., ORFD3a rSARS-CoV-2 was no longer detected in the lungs, while WT, ORFD6, ORFD7a, ORFD7b, and ORFD8 rSARS-CoV-2s decreased only ;1 log 10 to levels observed by 2 days p.i. (Fig. 6B) .

Furthermore, to evaluate the impact of viral infection in the lungs of infected animals, we performed gross pathology analysis on lungs collected at 2 and 4 days p.i. (Fig. 7A ). Both the WT and DORF rSARS-CoV-2s induced similar pathologies at 2 days p.i., with the WT, ORFD7a, and ORFD7b rSARS-CoV-2s inducing pathological lesions in more than 50% of the lung area (Fig. 7B) . Intriguingly, by 4 days p.i., only WT and ORFD8 rSARS-CoV-2-infected lungs maintained pathological lesions, while ORFD3a, ORFD6, ORFD7a, and ORFD7b rSARS-CoV-2-infected lungs appeared to recover from lesions observed at 2 days p.i. All together, these in vivo results provide new insight into the contribution of SARS-CoV-2 accessory ORF proteins in viral pathogenesis and disease, suggesting a major role of ORF3a and ORF6 and a smaller impact of ORF7a, ORF7b, and ORF8 on virulence and disease outcome.

Lastly, we evaluated the induction of chemokines and cytokines during infection in the lung using an 8-plex Luminex assay (Fig. 8) . We previously published that infection of K18 hACE2 transgenic mice with the SARS-CoV-2 WA-1/US strain induces local chemokine and cytokine storms in the lung (22) . Compared to mock-infected K18 hACE2 transgenic mice, infection of mice with rSARS-CoV-2/WT induced a significant production of type I interferon (IFN-a) and type II IFN (IFN-g) responses and chemo-attractants (e.g., CCL5/RANTES) at 2 days p.i. (Fig. 8A) . However, production of tumor necrosis factor alpha (TNF-a) (TH1), interleukin 6 (IL-6), IL-10 (TH2), and IL-17 (TH17) responses were low in rSARS-CoV-2/WT-infected K18 hACE2 transgenic mice (Fig. 8A ). All the ORF-deficient rSARS-CoV-2 constructs induced IFN responses at different levels, and the highest production of IFN-a and CCL5/RANTES was observed in mice infected with DORF6 rSARS-CoV-2. At 2 days p.i., no significant TH1 and TH2 responses were observed with any of the ORF-deficient rSARS-CoV-2s, except for DORF3a SARS-CoV-2, which induced significant levels of IL-10 (TH2). Conversely, elevated TH17 responses were observed for both DORF7b and DORF8 rSARS-CoV-2s. At 4 days p.i., all immunomodulator levels dropped to become nonsignificant compared to levels in rSARS-CoV-2/WT-infected K18 hACE2 transgenic mice, except for the levels of TNF-a induced by DORF7a SARS-CoV-2 infection, which remained significantly elevated. Importantly, when looking at predictors of the cytokine storm outcome (33) , the IL-6/IL-10 ratio was lower for DORF3a rSARS-CoV-2. Together with DORF3a rSARS-CoV-2 inducing early onset of morbidity, less mortality, lower lung viral titers, and less tissue damage, these results indicate a major role for ORF3a in viral pathogenesis. Interestingly, DORF8 rSARS-CoV-2 behaved like rSARS-CoV-2/WT (e.g., higher morbidity/mortality and viral titers), and as such, this mutant virus also presented the highest IL-6/IL-10 ratio at 2 days p.i. (Fig. 8B) . As expected, the IL-6/IL-10 ratio became normalized across all rSARS-CoV-2 constructs evaluated by 4 days p.i. (Fig. 8B) .

Viral proteins contribute to different aspects of disease outcome and pathogenesis during the course of viral infections (20, 30, 31) . Reverse-genetics systems allow for the deletion of viral proteins to gain insight into their contribution to viral replication, pathogenesis, transmission, and/or disease outcome, among other things (34) (35) (36) (37) . We recently established a state-of-the-art reverse-genetics system for the efficient rescue of rSARS-CoV-2/WT (21, 22) , which we used to generate DORF rSARS-CoV-2s and interrogate the contribution of the ORF3a, ORF6, ORF7a, ORF7b, and ORF8 accessory proteins in viral replication in vitro and in vivo. Similar studies have provided insight into the contribution of accessory ORF proteins in SARS-CoV infection in vitro and have identified a variety of functions, ranging from inhibition of host immune responses to activation of host cell death pathways (12-14, 17, 32, 34, 38-40) . However, to date, no study has provided insight into the role of SARS-CoV-2 ORF accessory proteins in viral replication in vitro and/or in pathogenesis in vivo. Our study using robust genetic systems and the validated K18 hACE2 transgenic mouse model of SARS-CoV-2 infection provides us with useful information on the contribution of SARS-CoV-2 ORF3a, 26, 27a, 27b, and 28 accessory proteins to viral pathogenesis.

In this study, we generated rSARS-CoV-2 constructs deficient in the ORF3a, 26, 27a, 27b, or 28 accessory protein (Fig. 1) and characterized them both in vitro (Fig. 2   FIG 8 (A) The cytokine and chemokine storms in the lungs of K18 hACE2 transgenic mice mock infected and infected with the WT or a DORF rSARS-CoV-2 were determined using an 8-plex panel mouse ProcartaPlex assay. (B) The IL-6/IL-10 ratio as a marker of the local cytokine storm induced by rSARS-CoV-2 was determined. A two-way ANOVA of K18 hACE2 transgenic mice mock infected or infected with the WT or an ORF-deficient rSARS-CoV-2 was carried out with 4 mice per time point, except for the mock-infected group (n = 2). and 4) and in vivo ( Fig. 5 and 8 ). Importantly, we were able to demonstrate the ORF-deficient nature of these rSARS-CoV-2s ( Fig. 2 and 3) . During our initial in vitro characterization, we first identified that ORF proteins contributed to early dissemination and formation of detectable viral plaques in Vero E6 cell monolayers; viruses lacking the ORF3a, 27a, 27b, and 28 proteins developed smaller plaques than rSARS-CoV-2/WT (Fig. 4) . This was a surprising finding, as we observed only an ;1-log 10 difference in growth kinetics between the WT and any of the DORF rSARS-CoV-2s (Fig. 4) . Additionally, the variation in plaque morphology and size was indicative of ORF deletions having an impact on viral dissemination and fitness. This is turn correlates with other studies that have correlated plaque size phenotype and size with virulence and viral fitness (23) (24) (25) .

To further determine the contribution of each ORF accessory protein in SARS-CoV-2 pathogenesis, we used our recently established K18 hACE2 transgenic mouse model (Fig. 5) (22) . This particular in vivo study is the first, to our knowledge, that analyzes the contribution of SARS-CoV-2 ORF accessory proteins in viral infection in a validated animal model of infection. We observed a broad range of morbidity and survival outcomes between each of the DORF rSARS-CoV-2s and rSARS-CoV-2/WT (Fig. 5) . SARS-CoV-2 ORF accessory proteins are encoded in the following order: ORF3a, 26, 27a, 27b, and 28. Our data collectively showed the greatest survival in mice infected with ORFD3a rSARS-CoV-2 (75%) and 100% mortality with ORFD8 rSARS-CoV-2. In this regard, a natural SARS-CoV-2 variant with a deletion of ORF8 has recently been isolated from patients presenting with COVID-19 symptoms (20) . Thus, our results with ORFD8 rSARS-CoV-2 in the K18 hACE2 transgenic mouse model correspond to those observed in people infected with a natural ORFD8 SARS-CoV-2 isolate (20) . Our findings with ORFD3a and ORFD6 rSARS-CoV-2s warrant further characterization, as there is limited insight into mechanistic exploitation of host pathways by ORF3a (12, 13, 32, 38, 39) . Since it is well known that SARS-CoV-2 ORF6 is a potent inhibitor of the host innate immune response (11, 31) , we were expecting low viral loads and an increased immune response with DORF6 rSARS-CoV-2; however, since SARS-CoV N protein also inhibits host immune responses (15, 41) , it is plausible that SARS-CoV-2 N protein may have a function similar to that of OFR6 and may be responsible for counteracting host innate immune and inflammatory responses. An increase in immune responses may in turn correlate with the decrease in weight loss and recovery in the mice infected with DORF6 rSARS-CoV-2. Our chemokine and cytokine analysis indicates that, specifically, ORF3a is implicated in driving the host immune response to SARS-CoV-2 during the early stages of infection. Indeed, in the absence of ORF3a, we observed a general decrease of the cytokine storm (IL-6/IL-10 ratio), especially at 2 days p.i., when significantly decreased viral titers and tissue damage were also observed in the lungs of animals infected with DORF3a rSARS-CoV-2. Mechanistic studies of innate and adaptive immune responses, as well as modulation of IFN secretion, ion signaling channels, and cellular apoptotic and/or necrosis pathways, are important in determining the contributions of these ORF accessory proteins in viral pathogenesis in vivo. This is currently the focus of our ongoing in vivo studies with these DORF rSARS-CoV-2s. Overall, as with what was described with rSARS-CoV, our study highlights the findings that SARS-CoV ORF3a, 23b, 26, 27a, and 27b had no significant impact on viral replication in vivo (34) but that ORF3a seems to be involved in virulence, as its absence decreases SARS-CoV-2 virulence.

Overall, this study demonstrates the robustness of our BAC-based reverse-genetics approach to generate rSARS-CoV-2s, including those with deletions of ORF accessory proteins, and provides information on the contributions of ORF3a, 26, 27a, 27b, and 28 accessory proteins in viral fitness in vitro (Vero E6 cells) and in vivo in our recently established K18 hACE2 transgenic mouse model of SARS-CoV-2 infection and COVID-19 disease (22) . Importantly, information from this study also provides novel insights for the generation of attenuated forms of SARS-CoV-2 for the development of live attenuated vaccines for the treatment of this important respiratory pathogen and its associated COVID-19 disease.

Biosafety. All the in vitro and in vivo experiments with an infectious natural isolate and rSARS-CoV-2 were conducted at appropriate biosafety level 3 (BSL3) and animal BSL3 (ABSL3) laboratories, respectively, at the Texas Biomedical Research Institute. Experiments were approved by the Texas Biomed Institutional Biosafety Committee (IBC) and Institutional Animal Care and Use Committee (IACUC).

Cells. African green monkey kidney epithelial cells (Vero E6, CRL-1586) were obtained from the American Type Culture Collection (ATCC; Bethesda, MD). The human embryonic kidney 293T (HEK293T) and the human lung carcinoma (A549) cell lines stably expressing hACE2 (hACE2-HEK293T and hACE2-A549, respectively) were obtained from BEI Resources (NR-52511 and NR-53821, respectively). All cell lines were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 5% (vol/vol) fetal bovine serum (FBS; VWR) and 100 units/ml penicillin-streptomycin (Corning).

Reverse-genetics system. The BAC harboring the entire viral genome of SARS-CoV-2 USA-WA1/ 2020 (GenBank accession no. MN985325) was described previously (21) . Deletion of individual accessory ORF proteins was achieved in viral fragment 1 by using inverse PCR and primer pairs containing a BsaI type IIS restriction endonuclease site. All the primer sequences are available upon request. Fragments, including those with individual deletions of accessory ORF proteins, were reassembled into the BAC using BamHI and RsrII restriction endonucleases.

Rescue of DORF rSARS-CoV-2s. Virus rescues were performed as previously described (21) . Briefly, confluent monolayers of Vero E6 cells (10 6 cells/well, 6-well plates, triplicates) were transfected with 4.0 mg/well of the SARS-CoV-2 BAC using Lipofectamine 2000. After 24 h, transfection medium was exchanged for p.i. medium (DMEM supplemented with 2% [vol/vol] FBS), and cells were split and seeded into T75 flasks 48 h posttransfection. After incubation for another 72 h, tissue culture supernatants were collected, labeled as P0, and stored at 280°C. After viral titration of the supernatant, the P0 virus was used to infect fresh Vero E6 cells at a multiplicity of infection (MOI) of 0.0001 to make new viral stocks. Tissue culture supernatants were collected 72 h p.i., aliquoted, labeled as P1, and stored at 280°C for future use. To sequence the viral stocks, viral RNA was purified using the Direct-zol RNA MiniPrep Plus (Zymo) kit according to the manufacturer's instructions. Whole-genome amplification and sequencing were performed as previously described (42) .

Immunofluorescence assay (IFA). Vero E6 cells (10 5 cells/well, 24-well plate format, triplicates) were mock infected or infected (MOI of 3) with the WT or a DORF rSARS-CoV-2. At 24 h p.i., cells were fixed with 10% formaldehyde solution at 4°C overnight and permeabilized using 0.5% (vol/vol) Triton X-100 in PBS for 15 min at room temperature. Cells were incubated overnight with 1 mg/ml of a SARS-CoV N protein cross-reactive polyclonal antibody at 4°C and a SARS-CoV-2 spike (S) cross-reactive monoclonal antibody (3B4), washed with PBS, and stained with a fluorescein isothiocyanate (FITC)-labeled goat antimouse IgG (1:200) and rhodamine-labeled goat anti-rabbit IgG (1:200). Nuclei were visualized by DAPI (49,6-diamidino-2-phenylindole) staining. After being washed with PBS, cells were visualized and imaged with an EVOS microscope (ThermoFisher Scientific).

Plaque assay and immunostaining. Confluent monolayers of Vero E6 cells (10 6 cells/well, 6-well plate format, triplicates) were infected with serially diluted viruses for 1 h at 37°C. After viral adsorption, cells were overlaid with p.i. medium containing 1% low-melting-point agar and incubated at 37°C. At 72 h p.i., cells were fixed overnight with 10% formaldehyde solution. For immunostaining, cells were permeabilized with 0.5% (vol/vol) Triton X-100 in PBS for 15 min at room temperature and immunostained using the SARS-CoV N protein cross-reactive monoclonal antibody 1C7C7 (1 mg/ml) and the Vectastain ABC kit (Vector Laboratories) by following the manufacturers' instructions. After the immunostaining, plates were visualized on a ChemiDoc imager (Bio-Rad). Viral plaque diameters were measured with a standard ruler in centimeters.

Virus growth kinetics. Confluent monolayers of Vero E6 cells (10 6 cells/well, 6-well plate format, triplicates) were infected (MOI of 0.01) with the WT or a DORF rSARS-CoV-2. After 1 h of virus adsorption at 37°C, cells were washed with PBS and incubated in p.i. medium at 37°C. At the indicated times after infection, viral titers in tissue culture supernatants were determined by plaque assay and immunostaining using the SARS-CoV N protein cross-reactive monoclonal antibody 1C7C7, as previously described (43) .

RT-PCR. Total RNA from Vero E6 cells (10 6 cells/well, 6-well plate format) infected (MOI of 0.01) with the WT or a DORF rSARS-CoV-2 was extracted with TRIzol reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. Reverse transcription-PCR (RT-PCR) amplification was performed using SuperScript II reverse transcriptase (Thermo Fisher Scientific) and an expanded high-fidelity PCR system (Sigma-Aldrich). The amplified DNA products were subjected to 0.7% agarose gel analysis, and the gelpurified PCR fragments were subjected to Sanger sequencing (ACGT). All primer sequences used for RT-PCR are available upon request. Methods for Illumina library preparation, sequencing, and analysis of recombinant viruses followed those previously described (21) .

Mice. Four-to 8-week-old specific-pathogen-free female B6.Cg-Tg(K18-ACE2)2Prlmn/J (stock no. 034860) K18 hACE2 transgenic mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Our previous studies did not show significant sex-dependent differences in morbidity, mortality, or viral titers (22) . K18 hACE2 transgenic mice were maintained in microisolator cages at ABSL3, provided sterile water and chow ad libitum, and acclimatized for 1 week prior to experimental manipulation. For morbidity and mortality studies, a total of 20 females were used (n = 4/group), whereas a total of 40 female mice (n = 4

Mice showing .25% loss of their initial body weight were defined as reaching the experimental endpoint and humanely euthanized. For viral titers and gross pathology analysis, K18 hACE2 transgenic mice were infected as described above but euthanized at 2 or 4 days p.i. Nasal turbinates and lung tissues were harvested and homogenized in 1 ml of PBS using a Precellys tissue homogenizer (Bertin Instruments) for viral titrations. Tissue homogenates were centrifuged at 21,500 Â g for 5 min, and supernatants were collected for determination of viral titer. Multiplex cytokine assay. Multiple cytokines and chemokines (IFN-a

SARS and MERS: recent insights into emerging coronaviruses

Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus

Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation

Molecular epidemiology, evolution and phylogeny of SARS coronavirus

From the handling of an outbreak by an unknown pathogen in Wuhan to the preparedness and response in the face of the emergence of Covid-19 in Mexico

2019-nCoV (Wuhan virus), a novel coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness

Properties of coronavirus and SARS-CoV-2

The UCSC SARS-CoV-2 Genome Browser

Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA

Activation and evasion of type I interferon responses by SARS-CoV-2

SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis. mSystems

The ORF3a protein of SARS-CoV-2 induces apoptosis in cells

The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death

Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists

7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase

The ORF7b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is expressed in virusinfected cells and incorporated into SARS-CoV particles

The transmembrane domain of the severe acute respiratory syndrome coronavirus ORF7b protein is necessary and sufficient for its retention in the Golgi complex

Discovery and genomic characterization of a 382-nucleotide deletion in ORF7b and ORF8 during the early evolution of SARS-CoV-2

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

Rescue of SARS-CoV-2 from a single bacterial artificial chromosome

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

Characterization of large and small-plaque variants in the Zika virus clinical isolate ZIKV/Hu/S36/Chiba/ 2016

Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children

Molecular determinants of plaque size as an indicator of dengue virus attenuation

Propagation, inactivation, and safety testing of SARS-CoV-2

Growth, detection, quantification, and inactivation of SARS-CoV-2

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV

SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

ORF3a mutation associated with higher mortality rate in SARS-CoV-2 infection

IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression

Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice

Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy

Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR

The role of reverse genetics systems in determining filovirus pathogenicity

SARS-Cov-2 ORF3a: mutability and function

ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation

Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination

Introductions and early spread of SARS-CoV-2 in the New York City area

Generation and characterization of recombinant SARS-CoV-2 expressing reporter genes

We thank Thomas Moran at the Icahn School of Medicine at Mount Sinai for providing us with the SARS-CoV cross-reactive N monoclonal antibody 1C7C7. We also thank BEI Resources for providing the SARS-CoV-2 USA-WA1/2020 isolate (NR-52281) and the hACE2-HEK293T (NR-52511) and hACE2-A549 (NR-53821) cell lines. Finally, we thank members at our institutes for their efforts in keeping them fully operational during the COVID-19 pandemic and the BSC and IACUC committees for reviewing our protocols in a time-efficient manner.This work was partly funded by the Center for Research for Influenza Pathogenesis (CRIP), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS; contract number HHSN272201400008C), by the Defense Advanced Research Projects Agency (HR0011-19-2-0020), and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384), and anonymous donors to A.G.-S.